Signaturefd, LLC Inhibrx, Inc. Transaction History

Signaturefd, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 31, 2024	BUY	$14.5 - $38.0 $10,759 - $28,196	742 Added 4637.5%	758 $28,000
Q3 2023 Nov 03, 2023	SELL	$15.75 - $26.31 $1,811 - $3,025	-115 Reduced 87.79%	16 $0
Q2 2023 Aug 01, 2023	BUY	$16.96 - $27.82 $1,950 - $3,199	115 Added 718.75%	131 $3,000
Q3 2022 Nov 08, 2022	BUY	$11.58 - $24.73 $185 - $395	16 New	16 $0
Q2 2022 Aug 10, 2022	SELL	$8.52 - $25.26 $724 - $2,147	-85 Closed	0 $0
Q1 2022 May 02, 2022	BUY	$19.89 - $43.18 $318 - $690	16 Added 23.19%	85 $2,000
Q4 2021 Jan 25, 2022	BUY	$26.75 - $46.02 $1,257 - $2,162	47 Added 213.64%	69 $3,000
Q3 2021 Oct 28, 2021	BUY	$25.18 - $37.81 $553 - $831	22 New	22 $1,000

18.6K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $565M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

Stay updated on Signaturefd, LLC with notifications on news.